FR08C0018I2 - - Google Patents

Info

Publication number
FR08C0018I2
FR08C0018I2 FR08C0018C FR08C0018C FR08C0018I2 FR 08C0018 I2 FR08C0018 I2 FR 08C0018I2 FR 08C0018 C FR08C0018 C FR 08C0018C FR 08C0018 C FR08C0018 C FR 08C0018C FR 08C0018 I2 FR08C0018 I2 FR 08C0018I2
Authority
FR
France
Prior art keywords
alkyl
hydrogen
alkynyl
alkenyl
tri
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR08C0018C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22860462&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR08C0018(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of FR08C0018I1 publication Critical patent/FR08C0018I1/fr
Application granted granted Critical
Publication of FR08C0018I2 publication Critical patent/FR08C0018I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Domestic Plumbing Installations (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
FR08C0018C 1994-04-18 2008-05-16 Active FR08C0018I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/229,261 US5362718A (en) 1994-04-18 1994-04-18 Rapamycin hydroxyesters
PCT/US1995/004603 WO1995028406A1 (fr) 1994-04-18 1995-04-14 Hydroxyesters de rapamicyne, leur procede d'obtention et preparations pharmaceutiques les contenant

Publications (2)

Publication Number Publication Date
FR08C0018I1 FR08C0018I1 (fr) 2008-07-18
FR08C0018I2 true FR08C0018I2 (fr) 2009-10-30

Family

ID=22860462

Family Applications (1)

Application Number Title Priority Date Filing Date
FR08C0018C Active FR08C0018I2 (fr) 1994-04-18 2008-05-16

Country Status (30)

Country Link
US (2) US5362718A (fr)
EP (3) EP1266899B1 (fr)
JP (1) JP3725901B2 (fr)
KR (1) KR100330800B1 (fr)
CN (1) CN1059905C (fr)
AT (3) ATE537176T1 (fr)
BR (1) BR9507323A (fr)
CA (1) CA2187024C (fr)
CY (2) CY2378B1 (fr)
CZ (1) CZ284567B6 (fr)
DE (3) DE69535363T2 (fr)
DK (2) DK0763039T3 (fr)
ES (3) ES2277975T3 (fr)
FR (1) FR08C0018I2 (fr)
HK (1) HK1048816B (fr)
HU (1) HU225915B1 (fr)
IL (1) IL113179A (fr)
LU (1) LU91438I2 (fr)
LV (1) LV13038B (fr)
MX (1) MX9604694A (fr)
NL (1) NL300348I2 (fr)
NZ (1) NZ283988A (fr)
PL (1) PL183178B1 (fr)
PT (2) PT1266899E (fr)
RU (1) RU2134267C1 (fr)
SI (2) SI0763039T1 (fr)
SK (1) SK281787B6 (fr)
TW (1) TW275631B (fr)
WO (1) WO1995028406A1 (fr)
ZA (1) ZA953090B (fr)

Families Citing this family (338)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6281015B1 (en) 1994-12-16 2001-08-28 Children's Medical Center Corp. Localized delivery of factors enhancing survival of transplanted cells
US6187757B1 (en) 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
US5922730A (en) * 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US8790391B2 (en) 1997-04-18 2014-07-29 Cordis Corporation Methods and devices for delivering therapeutic agents to target vessels
US6984635B1 (en) * 1998-02-13 2006-01-10 Board Of Trustees Of The Leland Stanford Jr. University Dimerizing agents, their production and use
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
US6331547B1 (en) 1999-08-18 2001-12-18 American Home Products Corporation Water soluble SDZ RAD esters
US6277983B1 (en) 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
TWI256395B (en) * 1999-09-29 2006-06-11 Wyeth Corp Regioselective synthesis of rapamycin derivatives
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US6670355B2 (en) * 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
JP2004507465A (ja) 2000-08-11 2004-03-11 ワイス エストロゲン受容体陽性癌腫の治療方法
EP1319008B1 (fr) * 2000-09-19 2008-10-15 Wyeth Esters de rapamycine hydrosolubles
US6399625B1 (en) * 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US20070276473A1 (en) * 2000-09-29 2007-11-29 Llanos Gerard H Medical Devices, Drug Coatings and Methods for Maintaining the Drug Coatings Thereon
US20060222756A1 (en) * 2000-09-29 2006-10-05 Cordis Corporation Medical devices, drug coatings and methods of maintaining the drug coatings thereon
AU9486901A (en) 2000-09-29 2002-04-08 Cordis Corp Coated medical devices
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
IL155952A0 (en) * 2000-11-28 2003-12-23 Wyeth Corp Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
PL409579A1 (pl) 2001-02-19 2015-03-02 Novartis Ag Leczenie raka
EP1385551B1 (fr) * 2001-04-06 2008-09-03 Wyeth Combinaisons antineoplasiques contenants du cci-779 (derivée de rapamycine) associe a la gemcitabine ou au fluorouracile
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
ZA200603888B (en) * 2001-06-01 2007-05-30 Wyeth Corp Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
BR0211986A (pt) 2001-08-22 2004-09-28 Wyeth Corp 29-enóis de rapamicina
MXPA04001523A (es) * 2001-08-22 2004-05-31 Wyeth Corp Dialdehidos de rapamicina.
US7682387B2 (en) 2002-04-24 2010-03-23 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US6939376B2 (en) * 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
BR0306811A (pt) * 2002-01-11 2004-10-26 Sankyo Co Composto, éster farmacologicamente aceitável do mesmo, composição farmacêutica e métodos para prevenção ou tratamento de doenças autoimunes, da artrite reumatóide e da rejeição causada pelo transplante de vários órgãos em um mamìfero
JP4547911B2 (ja) 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
PL215263B1 (pl) * 2002-02-25 2013-11-29 Elan Pharm Inc Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku
US20040024450A1 (en) * 2002-04-24 2004-02-05 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
PL372103A1 (en) 2002-05-16 2005-07-11 Novartis Ag Use of edg receptor binding agents in cancer
US7217796B2 (en) * 2002-05-24 2007-05-15 Schering Corporation Neutralizing human anti-IGFR antibody
EP1511473B8 (fr) 2002-05-27 2013-07-24 Novartis AG Alcanols bi-aromatiques
AU2003247483A1 (en) * 2002-05-30 2003-12-31 The Children's Hospital Of Philadelphia Methods for treatment of acute lymphocytic leukemia
CA2492153C (fr) 2002-07-16 2012-05-08 Biotica Technology Limited Production d'analogues de ligand fkbp polyketidiques
NZ537829A (en) 2002-07-30 2006-09-29 Wyeth Corp Parenteral formulations containing a rapamycin hydroxyester
EP1546369A4 (fr) * 2002-08-12 2007-01-17 Univ Michigan Diagnostic et traitement de maladies engendrees par des anomalies propres au trajet de la sclerose tubereuse (de bourneville)
DE60324609D1 (de) * 2002-09-17 2008-12-18 Wyeth Corp GRANULIERTE FORMULIERUNG DES RAPAMYCINESTERS CCl-779
EP1539270A1 (fr) * 2002-09-18 2005-06-15 Medtronic Vascular, Inc. Revetement a gradient de liberation de medicament controlee pour dispositifs medicaux
KR20080103117A (ko) 2002-09-24 2008-11-26 노파르티스 아게 탈수초성 장애의 치료에 있어서의 스핑고신-1-포스페이트 수용체 아고니스트
WO2004060283A2 (fr) 2002-12-16 2004-07-22 Nitromed, Inc. Composes a base de rapamycine nitrosee et nitrosylee, compositions et procedes d'utilisation
DK1592457T3 (da) * 2003-01-27 2012-10-22 Endocyte Inc Folat-vinblastin-konjugat som lægemiddel
AR042938A1 (es) * 2003-02-06 2005-07-06 Wyeth Corp Uso del cci-779 en el tratamiento de la fibrosis hepatica
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
ATE352301T1 (de) * 2003-04-22 2007-02-15 Wyeth Corp Antineoplastische zusammensetzungen
BRPI0409681A (pt) * 2003-04-23 2006-04-18 Wyeth Corp derivados de wortmanina solúveis em água
US7160867B2 (en) * 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
BRPI0410439A (pt) 2003-05-19 2006-06-06 Irm Llc compostos e composições imunossupressoras
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
TW200500065A (en) * 2003-05-21 2005-01-01 Wyeth Corp Antiarthritic combinations
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
WO2005017149A1 (fr) 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions et methodes pour une expression amelioree de polypeptides recombinants a partir d'un vecteur unique, faisant appel a un site de clivage peptidique
WO2005010010A1 (fr) * 2003-07-16 2005-02-03 Wyeth Isomere c cci-779
CN1829514A (zh) * 2003-07-25 2006-09-06 惠氏公司 Cci－779冻干制剂
KR20060057605A (ko) * 2003-08-07 2006-05-26 와이어쓰 Ｃｃｉ-779의 위치선택적 합성 방법
RU2345999C2 (ru) * 2003-09-03 2009-02-10 Уайт Аморфный 42-эфир рапамицина и 3-гидрокси-2(гидроксиметил)-2-метилпропионовой кислоты и содержащие его фармацевтические композиции
AR046194A1 (es) * 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
US7220755B2 (en) 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
PE20050928A1 (es) * 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
JP2007517879A (ja) * 2004-01-08 2007-07-05 ワイス Ｃｃｉ−７７９経口投与用の直接圧縮可能な医薬組成物
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
CA2561516A1 (fr) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinaisons d'inhibiteurs de transduction de signaux
AU2005238432A1 (en) * 2004-04-14 2005-11-10 Wyeth Process for preparing rapamycin 42-esters and FK-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies
AU2005233612A1 (en) 2004-04-14 2005-10-27 Wyeth Proline CCI-779 (proline-rapamycin 42-ester with 2,2-bis (hydroxymethyl) propionic acid) and two-step enzymatic synthesis of proline CCI-779 and CCI-779 using microbial lipase
JP4224115B2 (ja) * 2004-04-14 2009-02-12 ワイス ラパマイシン４２−エステル誘導体の位置特異的合成
CA2562164A1 (fr) * 2004-04-27 2005-11-10 Wyeth Marquage de rapamycine au moyen de methylases specifiques de la rapamycine
WO2006115509A2 (fr) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Immuno-potentialisateurs a petites molecules et analyses visant a detecter leur presence
US7714119B2 (en) * 2004-07-13 2010-05-11 Biosante Pharmaceuticals, Inc. AAV vector compositions and methods for enhanced expression of immunoglobulins using the same
JP5149620B2 (ja) 2004-07-23 2013-02-20 エンドサイト，インコーポレイテッド ２価リンカーおよびその結合体
MX2007001676A (es) * 2004-08-10 2007-04-12 Wyeth Corp Derivados de 42-ester de rapamicina con acido 2,2-bis(hidroximetil)propionico y metodos para hacer los mismos.
GB0417852D0 (en) 2004-08-11 2004-09-15 Biotica Tech Ltd Production of polyketides and other natural products
US7901451B2 (en) 2004-09-24 2011-03-08 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
BRPI0516308A2 (pt) * 2004-10-04 2010-06-15 Qlt Usa Inc composição fluida, métodos de tratamento de uma doença ou disfunção, métodos de liberação local ou sistêmica de um agente biológico, implantes, método de formação de um implante, kit de agente biológico e usos de uma composição fluida
US8313763B2 (en) * 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
KR20070070184A (ko) * 2004-10-28 2007-07-03 와이어쓰 자궁근종의 치료에 있어서 ｍＴＯＲ 억제제의 용도
US20080221660A1 (en) * 2004-10-28 2008-09-11 Medtronic Vascular, Inc. Platelet Gel for Treatment of Aneurysms
US8021849B2 (en) * 2004-11-05 2011-09-20 Siemens Healthcare Diagnostics Inc. Methods and kits for the determination of sirolimus in a sample
ES2364495T3 (es) 2005-02-03 2011-09-05 The General Hospital Corporation Método para tratar cáncer resistente a gefitinib.
CA2595766A1 (fr) * 2005-02-09 2006-08-17 Wyeth Polymrophe de cci-779 et utilisation de ce dernier
EP1855656A2 (fr) * 2005-02-15 2007-11-21 Wyeth Formulations orales de cci-779 biodisponibles
GB0503936D0 (en) 2005-02-25 2005-04-06 San Raffaele Centro Fond Method
JP2008531686A (ja) * 2005-03-02 2008-08-14 ワイス ラパマイシンの精製
CA2599580A1 (fr) * 2005-03-02 2006-09-08 Wyeth Recuperation de cci-779 a partir de solutions meres
GB0504544D0 (en) 2005-03-04 2005-04-13 Novartis Ag Organic compounds
GB0504994D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
US20100061994A1 (en) * 2005-03-11 2010-03-11 Rose Mary Sheridan Medical uses of 39-desmethoxyrapamycin and analogues thereof
EP1896018A2 (fr) 2005-03-11 2008-03-12 Biotica Technology Limited Utilisations medicales de 39-demethoxy-rapamicyne et ses analogues
EP1863816B1 (fr) * 2005-03-16 2014-06-25 Endocyte, Inc. Synthese et purification d'acide pteroique et des conjugues de celui-ci
WO2006113483A2 (fr) * 2005-04-15 2006-10-26 Schering Corporation Methodes et compositions pour le traitement ou la prevention du cancer
US7189582B2 (en) * 2005-04-27 2007-03-13 Dade Behring Inc. Compositions and methods for detection of sirolimus
US20070004767A1 (en) * 2005-06-30 2007-01-04 Gutmann David H Methods for treating neurofibromatosis 1
WO2007011707A2 (fr) 2005-07-15 2007-01-25 Micell Technologies, Inc. Enrobages polymeres renfermant de la poudre de medicament a morphologie commandee
WO2007011708A2 (fr) 2005-07-15 2007-01-25 Micell Technologies, Inc. Stent a revetement polymere renfermant de la rapamycine amorphe
US7632509B2 (en) * 2005-07-19 2009-12-15 Biosante Pharmaceuticals, Inc. Methods to express recombinant proteins from lentiviral vectors
HRP20140338T1 (hr) 2005-07-25 2014-06-20 Emergent Product Development Seattle, Llc Smanjenje broja b-stanica upotrebom molekula koje se specifiäśno vežu na cd37 i cd20
AU2006279304A1 (en) 2005-08-19 2007-02-22 Endocyte, Inc. Multi-drug ligand conjugates
EP1933845A2 (fr) 2005-08-25 2008-06-25 Medtronic Vascular, Inc. Polymeres biodegradables liberant de l'oxyde nitrique utiles comme dispositifs medicaux et revetements associes
JP5164167B2 (ja) 2005-08-30 2013-03-13 ユニバーシティー オブ マイアミ 免疫調節性腫瘍壊死因子受容体２５（ｔｎｆｒ２５）のアゴニスト、アンタゴニスト及び免疫毒素
WO2007056175A2 (fr) * 2005-11-04 2007-05-18 Wyeth 42-ester de rapamycine marque par isotope par un 41-methoxy
JP2009514870A (ja) 2005-11-04 2009-04-09 ワイス ｍＴＯＲインヒビター、ハーセプチン、および／またはＨＫＩ−２７２の抗悪性腫瘍性組み合わせ
US7622578B2 (en) * 2005-12-07 2009-11-24 Wyeth Scalable process for the preparation of a rapamycin 42-ester from a rapamycin 42-ester boronate
BRPI0619592A2 (pt) * 2005-12-07 2016-09-06 Wyeth Corp métodos para medir a qualidade da partícula de um composto de rapamicina, para determinar o tamanho de partícula médio de uma amostra e a cristalinidade de um composto de rapamicina, e para a purificação de rapamicina
AR058282A1 (es) * 2005-12-07 2008-01-30 Wyeth Corp Forma cristalina purificada de cci-779, un proceso para la preparacion del mismo, un metodo para monitorear la cristalizacion del cci-779, un kit y una composicion farmaceutica que lo comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
LT1983984T (lt) * 2006-02-02 2018-06-11 Novartis Ag Tuberozinės sklerozės gydymas
US20070203169A1 (en) * 2006-02-28 2007-08-30 Zhao Jonathon Z Isomers and 42-epimers of rapamycin ester analogs, methods of making and using the same
MX2008011458A (es) * 2006-03-07 2008-09-24 Wyeth Corp Procedimiento para preparar conjugados de polietilenglicol solubles en agua de inmunosupresores de macrolidos.
DE102006011507A1 (de) * 2006-03-14 2007-09-20 Lts Lohmann Therapie-Systeme Ag Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
US20070292922A1 (en) * 2006-03-31 2007-12-20 Cell Genesys, Inc. Regulated expression of recombinant proteins from adeno-associated viral vectors
CA2996768C (fr) 2006-04-26 2020-12-08 Micell Technologies, Inc. Revetements contenant plusieurs medicaments
US8241619B2 (en) 2006-05-15 2012-08-14 Medtronic Vascular, Inc. Hindered amine nitric oxide donating polymers for coating medical devices
GB0609962D0 (en) * 2006-05-19 2006-06-28 Biotica Tech Ltd Novel compounds
GB0609963D0 (en) * 2006-05-19 2006-06-28 Biotica Tech Ltd Novel compounds
CA2656112A1 (fr) * 2006-06-30 2008-05-08 Hanje Chen Polymeres biosensibles
US20080207671A1 (en) * 2006-07-31 2008-08-28 The Regents Of The University Of Michigan Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway
US20100266590A1 (en) * 2006-08-02 2010-10-21 Demetri George D Combination therapy
WO2008022256A2 (fr) * 2006-08-16 2008-02-21 Blagosklonny Mikhail V Procédés et compositions de prévention ou de traitement de maladies liées au vieillissement
US20080051691A1 (en) * 2006-08-28 2008-02-28 Wyeth Implantable shunt or catheter enabling gradual delivery of therapeutic agents
EP2083834B1 (fr) 2006-09-13 2017-06-21 Elixir Medical Corporation Composés de lactone macrocyclique et leurs procédés d'utilisation
TW200824713A (en) * 2006-10-18 2008-06-16 Wyeth Corp Processes for the synthesis of individual isomers of mono-PEG CCI-779
US20080097591A1 (en) 2006-10-20 2008-04-24 Biosensors International Group Drug-delivery endovascular stent and method of use
US8067055B2 (en) 2006-10-20 2011-11-29 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method of use
US7691402B2 (en) * 2006-11-06 2010-04-06 Medtronic Vascular, Inc. Block biodegradable copolymers for medical devices
WO2008058287A1 (fr) * 2006-11-10 2008-05-15 Syndax Pharmaceuticals, Inc. Association de ligands de era+ et d'inhibiteurs de l'histone désacétylase dans le traitement du cancer
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
WO2008065887A1 (fr) * 2006-11-27 2008-06-05 Terumo Kabushiki Kaisha Procédé de fabrication d'un dérivé de rapamycine o-alkylé, et dérivé de rapamycine o-alkylée
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
CA2679712C (fr) 2007-01-08 2016-11-15 Micell Technologies, Inc. Stents comportant des couches biodegradables
US7753962B2 (en) * 2007-01-30 2010-07-13 Medtronic Vascular, Inc. Textured medical devices
US20080188461A1 (en) * 2007-02-01 2008-08-07 Regents Of The University Of Michigan Compositions and methods for detecting, preventing and treating seizures and seizure related disorders
WO2008101231A2 (fr) 2007-02-16 2008-08-21 Endocyte, Inc. Procédés et compositions de traitement et de diagnostic d'une maladie rénale
US7815927B2 (en) * 2007-03-08 2010-10-19 Medtronic Vascular, Inc. Terpolymers for controlled release of bioactive agents from implantable medical devices
US7811600B2 (en) * 2007-03-08 2010-10-12 Medtronic Vascular, Inc. Nitric oxide donating medical devices and methods of making same
CN104127878A (zh) 2007-03-14 2014-11-05 恩多塞特公司 结合配体连接的微管溶素递药缀合物
TW200845960A (en) * 2007-04-05 2008-12-01 Wyeth Corp Wortmannin-rapalog conjugate and uses thereof
US20080245375A1 (en) * 2007-04-05 2008-10-09 Medtronic Vascular, Inc. Benign Prostatic Hyperplasia Treatments
TW200901989A (en) 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US20080306581A1 (en) * 2007-06-07 2008-12-11 Medtronic Vascular, Inc. Streamlined Stents
BRPI0812970A2 (pt) 2007-06-25 2019-09-24 Endocyte Inc conjugados contendo espaçadores hidrofílicos
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
US8852620B2 (en) 2007-07-20 2014-10-07 Medtronic Vascular, Inc. Medical devices comprising polymeric drug delivery systems with drug solubility gradients
US8273828B2 (en) * 2007-07-24 2012-09-25 Medtronic Vascular, Inc. Methods for introducing reactive secondary amines pendant to polymers backbones that are useful for diazeniumdiolation
US20090043378A1 (en) * 2007-08-10 2009-02-12 Medtronic Vascular, Inc. Biocompatible Polymer System for Extended Drug Release
US20090076060A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched temsirolimus
KR100930167B1 (ko) * 2007-09-19 2009-12-07 삼성전기주식회사 초광각 광학계
CA2701186C (fr) 2007-10-05 2017-09-19 Evonik Canada Inc. Polymeres reticules oligofluores et leurs utilisations
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
WO2009049426A1 (fr) 2007-10-19 2009-04-23 Interface Biologics Inc. Revêtements autodégradables
WO2009067453A1 (fr) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Combinaisons d'inhibiteurs de la hdac et d'inhibiteurs de protéasomes
WO2009089549A1 (fr) * 2008-01-11 2009-07-16 Massachusetts Eye & Ear Infirmary Animaux transgéniques de caspase dimérisable d'arrêt conditionnel
US20090222088A1 (en) * 2008-02-29 2009-09-03 Medtronic Vascular, Inc. Secondary Amine Containing Nitric Oxide Releasing Polymer Composition
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US20090232868A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Nitric Oxide Releasing Polymer Composition
US20090232863A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Biodegradable Carbon Diazeniumdiolate Based Nitric Oxide Donating Polymers
US20090240323A1 (en) * 2008-03-20 2009-09-24 Medtronic Vascular, Inc. Controlled Degradation of Magnesium Stents
EP2278966B1 (fr) 2008-03-21 2019-10-09 The University of Chicago Traitement avec des antagonistes des opioïdes et des inhibiteurs mtor
US20090253733A1 (en) * 2008-04-02 2009-10-08 Biointeractions, Ltd. Rapamycin carbonate esters
EP2365003A1 (fr) 2008-04-11 2011-09-14 Emergent Product Development Seattle, LLC Produits d'immunothérapie de CD37 et combinaison avec un produit chimiothérapique bifonctionnel de celui-ci
US20110098241A1 (en) * 2008-04-14 2011-04-28 Poniard Pharmaceuticals, Inc. Rapamycin analogs as anti-cancer agents
SG192523A1 (en) 2008-04-17 2013-08-30 Micell Technologies Inc Stents having bioabsorbable layers
US20090269480A1 (en) * 2008-04-24 2009-10-29 Medtronic Vascular, Inc. Supercritical Fluid Loading of Porous Medical Devices With Bioactive Agents
US20090299464A1 (en) * 2008-06-02 2009-12-03 Medtronic Vascular, Inc. Reducing Bioabsorbtion Time of Polymer Coated Implantable Medical Devices Using Polymer Blends
US20090297576A1 (en) * 2008-06-02 2009-12-03 Medtronic Vascular, Inc. Local Delivery of PAR-1 Antagonists to Treat Vascular Complications
ES2692769T3 (es) 2008-06-17 2018-12-05 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
KR20110020928A (ko) 2008-06-20 2011-03-03 노파르티스 아게 다발성 경화증을 치료하기 위한 소아용 조성물
EP2313122B1 (fr) 2008-07-17 2019-03-06 Micell Technologies, Inc. Dispositif médical d administration de médicament
US9510856B2 (en) 2008-07-17 2016-12-06 Micell Technologies, Inc. Drug delivery medical device
CN101676291B (zh) 2008-09-18 2012-05-09 上海海和药物研究开发有限公司 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途
EP2352459A4 (fr) * 2008-10-03 2013-09-25 Elixir Medical Corp Composés lactones macrocycliques et leurs méthodes d'utilisation
US20100092534A1 (en) * 2008-10-10 2010-04-15 Medtronic Vascular, Inc. Combination Local Delivery Using a Stent
US20100092535A1 (en) * 2008-10-10 2010-04-15 Medtronic Vascular, Inc. Nanoporous Drug Delivery System
EP2365802B1 (fr) 2008-11-11 2017-08-02 The Board of Regents,The University of Texas System Microcapsules de rapamycine et l'usage pour le traitement du cancer
US20100131001A1 (en) * 2008-11-24 2010-05-27 Medtronic Vascular, Inc. Targeted Drug Delivery for Aneurysm Treatment
US20100131051A1 (en) * 2008-11-24 2010-05-27 Medtronic Vascular, Inc. Systems and Methods for Treatment of Aneurysms Using Zinc Chelator(s)
US20100152832A1 (en) * 2008-12-12 2010-06-17 Medtronic Vascular, Inc. Apparatus and Methods for Treatment of Aneurysms With Fibrin Derived Peptide B-Beta
CA2747558A1 (fr) 2008-12-18 2010-07-15 Novartis Ag Nouveaux sels
CN102256942B (zh) 2008-12-18 2013-07-24 诺瓦提斯公司 1-(4-{1-[(e)-4-环己基-3-三氟甲基-苄氧基亚氨基]-乙基}-2-乙基-苄基)-氮杂环丁烷-3-甲酸的多晶型物
PT2676953T (pt) 2008-12-18 2017-06-29 Novartis Ag Sal hemifumarato de ácido 1-[4-[1-(4-ciclo-hexil-3-trifluorometil-benziloxi-imino)-etil]-2-etil-benzil]-azetidino-3-carboxílico para utilização no tratamento de doenças mediadas por linfócitos
US8158187B2 (en) * 2008-12-19 2012-04-17 Medtronic Vascular, Inc. Dry diazeniumdiolation methods for producing nitric oxide releasing medical devices
US20100198338A1 (en) * 2009-01-30 2010-08-05 Medtronic Vascular, Inc., A Delaware Corporation Hydrogen Sulfide Donating Polymers
WO2010091306A1 (fr) 2009-02-05 2010-08-12 Tokai Pharmaceuticals Nouveaux promédicaments à base d'inhibiteurs cyp17 stéroïdiens/anti-androgènes
US20100227799A1 (en) * 2009-03-09 2010-09-09 Medtronic Vascular, Inc. Simultaneous photodynamic therapy and photo induced polymerization
WO2010120552A2 (fr) 2009-04-01 2010-10-21 Micell Technologies, Inc. Endoprothèses enduites
US8236341B2 (en) * 2009-04-02 2012-08-07 Medtronic Vascular, Inc. Poly(tetrafluoroethylene) polymer with nitric oxide donating surface
US20100256728A1 (en) * 2009-04-07 2010-10-07 Medtronic Vascular, Inc. Semi-Permiable Biodegradable Stent Graft and Uses Thereof
US8709465B2 (en) * 2009-04-13 2014-04-29 Medtronic Vascular, Inc. Diazeniumdiolated phosphorylcholine polymers for nitric oxide release
CN102481361B (zh) 2009-04-16 2014-10-22 默沙东公司 用于治疗癌症的组合物和方法
WO2010121187A2 (fr) 2009-04-17 2010-10-21 Micell Techologies, Inc. Endoprothèses vasculaires ayant une élution contrôlée
US8716307B2 (en) 2009-05-13 2014-05-06 The Trustees Of The University Of Pennsylvania Combination antineoplastic therapy
JP2013501057A (ja) 2009-08-03 2013-01-10 ユニバーシティー・オブ・マイアミ 制御性ｔ細胞のｉｎｖｉｖｏにおける増殖
WO2011051960A2 (fr) 2009-09-25 2011-05-05 Cadila Healthcare Limited Procédé de préparation de dérivés de rapamycine
MX2012004780A (es) 2009-10-23 2012-08-23 Lilly Co Eli Inhibidores de akt.
CA2777128A1 (fr) 2009-10-30 2011-05-05 Ariad Pharmaceuticals, Inc. Procedes et compositions pour le traitement du cancer
US20170079962A1 (en) 2009-11-11 2017-03-23 Rapamycin Holdings, Llc Oral Rapamycin Preparation and Use for Stomatitus
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
WO2011072398A1 (fr) 2009-12-18 2011-06-23 Interface Biologics, Inc. Administration locale de médicaments à partir de revêtements auto-assemblés
US8182830B2 (en) * 2010-01-05 2012-05-22 Medtronic Vascular, Inc. Hydrogen sulfide generating polymers
AU2011210227A1 (en) * 2010-01-28 2012-08-30 Fresenius Kabi Oncology Ltd. Process for the preparation of Temsirolimus and its intermediates
US11369498B2 (en) 2010-02-02 2022-06-28 MT Acquisition Holdings LLC Stent and stent delivery system with improved deliverability
JP2013521002A (ja) 2010-03-05 2013-06-10 プレジデント アンド フェロウズ オブ ハーバード カレッジ 誘導樹状細胞組成物及びその使用
CA2797110C (fr) 2010-04-22 2020-07-21 Micell Technologies, Inc. Endoprotheses et autres dispositifs ayant un revetement de matrice extracellulaire
EP2563391B1 (fr) 2010-04-27 2020-08-26 Roche Glycart AG Polythérapie d'un anticorps CD20 afucosylaté avec un inhibiteur mTOR
WO2011151704A2 (fr) 2010-06-02 2011-12-08 Fresenius Kabi Oncology Ltd. Compositions pharmaceutiques stables d'esters de rapamycine
EP2593039B1 (fr) 2010-07-16 2022-11-30 Micell Technologies, Inc. Dispositif médical d'administration de médicament
EP2601201B1 (fr) * 2010-08-04 2014-09-24 Meril Life Sciences Pvt. Ltd. Procédé pour la préparation des composés nouveaux du 42-o-(hétéroalkyloxy) rapamycin avec les propriétaires antiprolifiques.
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
JP2014503499A (ja) 2010-11-18 2014-02-13 シンタ ファーマスーティカルズ コーポレーション 低酸素状態に基づく治療に適した被験体の事前選択
EP2640384A1 (fr) 2010-11-18 2013-09-25 Synta Pharmaceuticals Corp. Présélection de patients pour un traitement thérapeutique fondé sur un état hypoxique, avec des agents sensibles à l'oxygène
EP2455104B1 (fr) 2010-11-19 2013-07-17 Universitätsklinikum Freiburg Hydrogels de PEG bio-fonctionnalisés et solubles dépendant à un stimulus
CN102020662B (zh) * 2011-01-07 2013-02-13 天津市炜杰科技有限公司 一种驮瑞塞尔制备方法
CA2827673C (fr) 2011-02-18 2020-10-27 Novartis Pharma Ag Pluritherapie impliquant un inhibiteur de mtor et un inhibiteur de jak
MX2013011412A (es) * 2011-04-01 2014-04-30 Sandoz Ag Acilacion regioselectiva de rapamicina en la posicion c-42.
WO2012143879A1 (fr) 2011-04-21 2012-10-26 Piramal Healthcare Limited Forme cristalline d'un sel d'un dérivé de morpholinosulfonylindole et son procédé de préparation
EP2702173A1 (fr) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Utilisation de signatures de gènes de tem dans la découverte de médicaments contre le cancer, diagnostics et traitement du cancer
JP2014516075A (ja) 2011-06-06 2014-07-07 シェブロン フィリップス ケミカル カンパニー エルピー 癌治療のためのメタロセン化合物の使用
EP2532740A1 (fr) 2011-06-11 2012-12-12 Michael Schmück Préparations de lymphocytes T à mémoire centrale CD4+ et CD8+ spécifiques aux antigènes pour thérapie de lymphocyte T adoptif
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
WO2013013708A1 (fr) 2011-07-26 2013-01-31 Fundació Institut D'investigació Biomèdica De Bellvitge Traitement du rejet aigu dans une transplantation rénale
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
CN102424829B (zh) * 2011-10-26 2013-10-16 苏州汉酶生物技术有限公司 一种酶催化合成坦西莫司的方法
CA2859089A1 (fr) 2011-12-16 2013-06-20 Pfizer Inc. Combinaison d'inotuzumab ozogamicine et de torisel pour le traitement du cancer
GB201122305D0 (en) 2011-12-23 2012-02-01 Biotica Tech Ltd Novel compound
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
CN102796115B (zh) * 2012-05-25 2015-07-15 上海现代制药股份有限公司 一种坦西莫司的制备方法
CN103705925B (zh) 2012-09-29 2018-03-30 段磊 抑制PI3K/AKT/mTOR信号通路的药物组合
US9750728B2 (en) 2012-09-29 2017-09-05 Targeted Therapeutics, Llc Method and pharmaceutical composition for inhibiting PI3K/AKT/mTOR signaling pathway
US20150290176A1 (en) 2012-10-12 2015-10-15 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors to treat vascular cognitive impairment
EP2908818A4 (fr) 2012-10-16 2016-07-13 Endocyte Inc Conjugués d'administration de médicament contenant des acides aminés artificiels et procédés d'utilisation
US20150258127A1 (en) 2012-10-31 2015-09-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
WO2014110258A1 (fr) 2013-01-09 2014-07-17 Podack Eckhard R Compositions et procédés pour la régulation de lymphocytes t régulateurs à l'aide d'une protéine d'une fusion tl1a-ig
EP4303232A3 (fr) 2013-02-15 2024-04-17 The Regents of The University of California Récepteur d'antigène chimère et procédés d'utilisation de celui-ci
AU2014248508B2 (en) 2013-03-12 2018-11-08 Micell Technologies, Inc. Bioabsorbable biomedical implants
EP2968281B1 (fr) 2013-03-13 2020-08-05 The Board of Regents of The University of Texas System Inhibiteurs de mtor pour la prévention de la croissance de polypes intestinaux
KR20150127720A (ko) 2013-03-14 2015-11-17 유니버시티 오브 매릴랜드, 발티모어 안드로겐 수용체 하향 조절제 및 그의 용도
EP2994758B1 (fr) 2013-05-08 2017-12-20 Opthea Limited Marqueurs biologiques de la dégénérescence maculaire liée à l'âge (dmla)
WO2014186532A1 (fr) 2013-05-15 2014-11-20 Micell Technologies, Inc. Implants biomedicaux bioabsorbables
CN103421023B (zh) * 2013-07-30 2015-09-23 福建省微生物研究所 一种替西罗莫司的合成工艺
CA2920317A1 (fr) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarqueurs pour le traitement de troubles neoplasiques a l'aide de therapies ciblant les androgenes
CN105899232A (zh) 2013-11-13 2016-08-24 诺华股份有限公司 用于增强免疫应答的mTOR抑制剂
EP2878312A1 (fr) 2013-12-02 2015-06-03 Albert-Ludwigs-Universität Freiburg Nanosupports de PEGylation réversible
ES2918501T3 (es) 2013-12-19 2022-07-18 Novartis Ag Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
AU2014373683B2 (en) 2013-12-31 2020-05-07 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
WO2015108912A1 (fr) 2014-01-16 2015-07-23 MUSC Foundation for Research and Development Nanosupports ciblés pour l'administration d'agents immunosuppresseurs
US20170081411A1 (en) 2014-03-15 2017-03-23 Novartis Ag Regulatable chimeric antigen receptor
EP3593812A3 (fr) 2014-03-15 2020-05-27 Novartis AG Traitement du cancer à l'aide d'un récepteur d'antigène chimérique
CA2943609A1 (fr) 2014-03-27 2015-10-01 The Brigham And Women's Hospital, Inc. Conjugues de medicaments actives metaboliquement pour vaincre la resistance dans une therapie du cancer
AU2015244039B2 (en) 2014-04-07 2021-10-21 Novartis Ag Treatment of cancer using anti-CD19 chimeric antigen receptor
MX2016015569A (es) 2014-06-02 2017-04-25 Children´S Medical Center Corp Metodos y composiciones para inmunomodulacion.
WO2016014530A1 (fr) 2014-07-21 2016-01-28 Novartis Ag Combinaisons de faibles doses renforçant l'immunité d'inhibiteurs de mtor et car
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
SG10201913765YA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
CN104086564B (zh) * 2014-07-30 2019-02-05 江苏奥赛康药业股份有限公司 一种高纯度坦罗莫司的制备方法
ES2781175T3 (es) 2014-07-31 2020-08-31 Novartis Ag Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
CA2958200A1 (fr) 2014-08-14 2016-02-18 Novartis Ag Traitement du cancer a l'aide du recepteur d'antigene chimerique gfr alpha-4
ES2791248T3 (es) 2014-08-19 2020-11-03 Novartis Ag Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
WO2016040806A1 (fr) 2014-09-11 2016-03-17 The Regents Of The University Of California Inhibiteurs de mtorc1
KR20250067191A (ko) 2014-09-17 2025-05-14 노파르티스 아게 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
EP2997977A1 (fr) 2014-09-19 2016-03-23 Fundación de la Comunidad Valenciana Centro de Investigación Principe Felipe Inhibiteurs de MTOR spécifiques dans le traitement d'une adrénoleucodystrophie à liaison X
KR20170068504A (ko) 2014-10-08 2017-06-19 노파르티스 아게 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
US20190054117A1 (en) 2014-12-19 2019-02-21 Novartis Ag Dimerization switches and uses thereof
US10377818B2 (en) 2015-01-30 2019-08-13 The Board Of Trustees Of The Leland Stanford Junior University Method of treating glioma
US20180140602A1 (en) 2015-04-07 2018-05-24 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
SG11201708516YA (en) 2015-04-17 2017-11-29 David Maxwell Barrett Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
EP3286211A1 (fr) 2015-04-23 2018-02-28 Novartis AG Traitement du cancer à l'aide de protéine récepteur antigénique chimérique et un inhibiteur de protéine kinase
HK1245095A1 (zh) 2015-05-20 2018-08-24 Novartis Ag 依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合
EP3303634B1 (fr) 2015-06-03 2023-08-30 The Regents of The University of California Variants de cas9 et procédés d'utilisation associés
WO2017029391A1 (fr) 2015-08-20 2017-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Nouvelle méthode de traitement du cancer
IL258574B2 (en) 2015-11-11 2025-01-01 Novartis Ag Uses of myostatin antagonists, combinations containing them and their uses
US10765665B2 (en) 2015-11-24 2020-09-08 Melin Jeffrey Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases
WO2020047527A2 (fr) 2018-09-02 2020-03-05 F1 Bioventures, Llc Procédés et compositions pour modifier génétiquement des lymphocytes dans le sang ou dans des pbmc enrichies
EP3442540A4 (fr) 2016-04-14 2019-12-18 Spinnaker Biosciences Inc. Matériaux de silicium poreux comprenant un silicate métallique pour l'administration d'agents thérapeutiques
EP3487878A4 (fr) 2016-07-20 2020-03-25 University of Utah Research Foundation Lymphocytes car-t cd229 et leurs procédés d'utilisation
WO2018057788A1 (fr) 2016-09-22 2018-03-29 Mercator Medsystems, Inc. Traitement de la resténose par le temsirolimus
EP3523331A1 (fr) 2016-10-07 2019-08-14 Novartis AG Récepteurs antigéniques chimériques pour le traitement du cancer
CN110114070A (zh) 2016-11-23 2019-08-09 诺华公司 使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法
JP2020507632A (ja) 2017-02-10 2020-03-12 マウント タム セラピューティクス, インコーポレイテッドMount Tam Therapeutics, Inc. ラパマイシン類似体
AU2018226884B2 (en) 2017-03-03 2024-11-07 Exuma Biotech, Corp. Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof
WO2018201056A1 (fr) 2017-04-28 2018-11-01 Novartis Ag Cellules exprimant un récepteur antigénique chimérique ciblant le bcma, et polythérapie comprenant un inhibiteur de gamma sécrétase
EP3848065B1 (fr) 2017-05-15 2023-07-26 C. R. Bard, Inc. Dispositif médical à revêtement d'élution de médicament et à couche intermédiaire
CN108948045A (zh) * 2017-05-20 2018-12-07 鲁南制药集团股份有限公司 一种替西罗莫司的制备方法
AU2018272061A1 (en) 2017-05-26 2020-01-02 Mercator Medsystems, Inc. Combination therapy for treatment of restenosis
WO2019002168A1 (fr) 2017-06-26 2019-01-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques de traitement du syndrome d'olmsted
EP3652306A1 (fr) 2017-07-13 2020-05-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés pour augmenter la capacité immunosuppressive et d'expansion d'une population de cd8 + cd45rclow/-tregs
AR112834A1 (es) 2017-09-26 2019-12-18 Novartis Ag Derivados de rapamicina
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
CN212631328U (zh) 2018-03-14 2021-03-02 墨卡托医疗系统公司 用于局部药物递送的医疗器械
EP3784351A1 (fr) 2018-04-27 2021-03-03 Novartis AG Thérapies reposant sur des cellules car-t présentant une efficacité améliorée
CN112368289B (zh) 2018-05-01 2024-02-20 锐新医药公司 作为mtor抑制剂的c26-连接的雷帕霉素类似物
IL300091A (en) 2018-05-01 2023-03-01 Revolution Medicines Inc C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
EP3796948A4 (fr) 2018-05-22 2022-03-02 Interface Biologics Inc. Compositions et procédés d'administration de médicaments à une paroi de vaisseau
CN113164557A (zh) 2018-07-23 2021-07-23 因柯利尔疗法公司 治疗神经性病症的方法
JP2022510573A (ja) 2018-07-23 2022-01-27 エンクリアー セラピーズ， インク． 神経障害の治療方法
WO2020053125A1 (fr) 2018-09-10 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de traitement de la neurofibromatose
CN113164576A (zh) 2018-10-05 2021-07-23 圣安娜儿童癌症研究中心 嵌合抗原受体(car)组
EP3632460A1 (fr) 2018-10-05 2020-04-08 St. Anna Kinderkrebsforschung Groupe de récepteurs d'antigènes chimériques (cars)
CA3112310C (fr) 2018-10-05 2025-05-06 Universitat Fur Bodenkultur Wien Groupe de récepteurs d’antigènes chimériques (car)
EP3632461A1 (fr) 2018-10-05 2020-04-08 St. Anna Kinderkrebsforschung Groupe de récepteurs d'antigène chimérique (cars)
EP3880266B1 (fr) 2018-11-14 2025-05-07 Lutonix, Inc. Dispositif médical avec revêtement à élution de médicament sur un dispositif à surface modifiée
MX2021007247A (es) 2018-12-18 2021-07-15 Novartis Ag Derivados de rapamicina.
JPWO2020130125A1 (ja) 2018-12-21 2021-11-04 第一三共株式会社 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
WO2020163594A1 (fr) 2019-02-07 2020-08-13 The Regents Of The University Of California Agents de liaison à l'immunophiline et leurs utilisations
WO2020209828A1 (fr) 2019-04-08 2020-10-15 Bard Peripheral Vascular, Inc. Dispositif médical portant un revêtement d'élution de médicament sur une surface modifiée de dispositif
JP2022526671A (ja) 2019-04-11 2022-05-25 エンクリアー セラピーズ， インク． 脳脊髄液の改善の方法ならびにそのためのデバイスおよびシステム
MX2022000279A (es) 2019-07-07 2022-02-03 Olema Pharmaceuticals Inc Regimenes de antagonistas del receptor de estrogeno.
CN113372359A (zh) * 2020-03-10 2021-09-10 鲁南制药集团股份有限公司 一种坦西莫司的制备方法
JP2023543868A (ja) 2020-09-29 2023-10-18 エンクリアー セラピーズ， インク． くも膜下液管理方法およびシステム
EP4240356A1 (fr) 2020-11-03 2023-09-13 RDiscovery, LLC Thérapies pour le traitement du cancer et de maladies associées à une déficience en phagocytose
CA3223081A1 (fr) 2021-07-15 2023-01-19 Samir Mitragotri Compositions et methodes associees a des cellules comprenant des particules adherees
AU2023275778A1 (en) 2022-05-25 2024-12-12 Revolution Medicines, Inc. Methods of treating cancer with an mtor inhibitor
JP2025521677A (ja) 2022-07-06 2025-07-10 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 増殖性糸球体腎炎を処置するための方法
US20260060969A1 (en) 2022-08-04 2026-03-05 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of lymphoproliferative disorders
EP4615431A1 (fr) 2022-11-11 2025-09-17 Astrazeneca AB Polythérapies pour le traitement du cancer

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) * 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US4316885A (en) * 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US4375464A (en) * 1981-11-19 1983-03-01 Ayerst, Mckenna & Harrison Inc. Antibiotic AY24,668 and process of preparation
US4650803A (en) * 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5023264A (en) * 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
US5023263A (en) * 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
US5023262A (en) * 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
US5130307A (en) * 1990-09-28 1992-07-14 American Home Products Corporation Aminoesters of rapamycin
US5378696A (en) * 1990-09-19 1995-01-03 American Home Products Corporation Rapamycin esters
US5221670A (en) * 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
PT98990A (pt) * 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5233036A (en) * 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5080899A (en) * 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5120842A (en) * 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
IL101353A0 (en) * 1991-04-03 1992-11-15 American Home Prod Pharmaceutical compositions for treating diabetes
US5100883A (en) * 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
FI921595A7 (fi) 1991-04-17 1992-10-18 American Home Prod Rapamysiinikarbamaatteja
US5194447A (en) * 1992-02-18 1993-03-16 American Home Products Corporation Sulfonylcarbamates of rapamycin
US5118678A (en) * 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5091389A (en) * 1991-04-23 1992-02-25 Merck & Co., Inc. Lipophilic macrolide useful as an immunosuppressant
US5102876A (en) * 1991-05-07 1992-04-07 American Home Products Corporation Reduction products of rapamycin
US5138051A (en) * 1991-08-07 1992-08-11 American Home Products Corporation Rapamycin analogs as immunosuppressants and antifungals
US5118677A (en) * 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
ATE135583T1 (de) 1991-06-18 1996-04-15 American Home Prod Verwendung von rapamycin zur behandlung von t- zellen lymphom/leukämie bei erwachsenen
ZA924953B (en) 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5169851A (en) * 1991-08-07 1992-12-08 American Home Products Corporation Rapamycin analog as immunosuppressants and antifungals
US5286731A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5286730A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5151413A (en) * 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
US5177203A (en) * 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5262423A (en) * 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5260300A (en) * 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5385908A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent

Also Published As

Publication number Publication date
TW275631B (fr) 1996-05-11
EP0763039A1 (fr) 1997-03-19
DE69529897T2 (de) 2003-11-06
EP1760083B1 (fr) 2011-12-14
ES2277975T3 (es) 2007-08-01
EP0763039B3 (fr) 2017-04-05
CN1059905C (zh) 2000-12-27
ATE537176T1 (de) 2011-12-15
LV13038B (en) 2003-10-20
ZA953090B (en) 1996-10-14
CZ284567B6 (cs) 1999-01-13
HUT77410A (hu) 1998-04-28
ES2191704T3 (es) 2003-09-16
HK1048816A1 (en) 2003-04-17
EP1266899B1 (fr) 2007-01-03
SI0763039T1 (en) 2003-08-31
DE69529897D1 (de) 2003-04-17
JPH09512018A (ja) 1997-12-02
AU2247495A (en) 1995-11-10
SI1266899T1 (sl) 2007-04-30
PT1266899E (pt) 2007-02-28
PT763039E (pt) 2003-06-30
BR9507323A (pt) 1997-09-30
LU91438I2 (fr) 2008-07-15
PL316948A1 (en) 1997-02-17
DE122008000023I1 (de) 2008-08-14
AU679854B2 (en) 1997-07-10
ES2191704T7 (es) 2017-07-10
HK1048816B (en) 2007-04-04
FR08C0018I1 (fr) 2008-07-18
DE69535363D1 (de) 2007-02-15
WO1995028406A1 (fr) 1995-10-26
IL113179A (en) 1998-06-15
NL300348I2 (nl) 2008-09-01
HU9602893D0 (en) 1996-12-30
ATE350384T1 (de) 2007-01-15
NZ283988A (en) 1998-07-28
US5362718A (en) 1994-11-08
CA2187024C (fr) 2004-08-10
MX9604694A (es) 1998-01-31
USRE44768E1 (en) 2014-02-18
NL300348I1 (nl) 2008-07-01
HU225915B1 (en) 2007-12-28
PL183178B1 (pl) 2002-05-31
CA2187024A1 (fr) 1995-10-26
ATE234307T1 (de) 2003-03-15
JP3725901B2 (ja) 2005-12-14
DE69535363T2 (de) 2007-04-19
CY2008012I1 (el) 2009-11-04
SK133096A3 (en) 1997-04-09
EP0763039B1 (fr) 2003-03-12
DE69529897T3 (de) 2017-08-17
DK0763039T3 (da) 2003-05-05
SK281787B6 (sk) 2001-07-10
ES2375730T3 (es) 2012-03-05
KR970702283A (ko) 1997-05-13
EP1760083A1 (fr) 2007-03-07
CY2008012I2 (el) 2009-11-04
EP1266899A2 (fr) 2002-12-18
RU2134267C1 (ru) 1999-08-10
CY2378B1 (en) 2004-06-04
HK1011352A1 (en) 1999-07-09
KR100330800B1 (ko) 2002-11-20
CZ305296A3 (en) 1997-08-13
IL113179A0 (en) 1995-06-29
EP1266899A3 (fr) 2003-05-28
CN1149296A (zh) 1997-05-07
DK1266899T3 (da) 2007-01-29

Similar Documents

Publication Publication Date Title
FR08C0018I2 (fr)
AU3822193A (en) Azole compounds, their production and use
CA2076430A1 (fr) Derive pyrrolidylthiocarbapeneme
AU2267195A (en) Dc-89 derivative
DE69407422D1 (en) Androstenone
DK0655065T3 (fr)
DE3567455D1 (en) Triazole antifungal agents
IL80115A0 (en) Bicyclic compounds,their preparation and their use as pesticides
EP0601191A4 (en) Novel tetracyclic compound.
EP0080570A3 (en) Ailanthone derivatives
GR3021427T3 (en) Indole derivative